The primary focus of the project will be to develop a 5 Lipoxygenase (5-LO) genotyping panel for VIA-2291, VIA’s lead candidate for cardiovascular disease, as well as a next-generation all-inclusive ADME/Tox panel. Additionally, the project includes development of genotyping panels broadly applicable to future clinical trials.
Funding of the program will be approximately $5 million at current US and Canadian exchange rates, with VIA providing approximately $2.4 million of this funding for expenditures planned in its acute coronary syndrome (ACS) clinical trial, and approximately $200,000 for costs related to the pharmacogenomics sub-study. Genome Quebec and other companies will be providing the balance of the co-funding.
Lawrence Cohen, CEO, said: “We believe that this sub-study will generate important information on the pharmacogenomics of our study patients, and will provide additional insight into the role we believe VIA-2291 will play in reducing vascular inflammation in ACS patients with atherosclerosis.”